NHAS
APGE icon

Novo Holdings A/S’s Apogee Therapeutics APGE Stock Holding History

Novo Holdings A/S’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.9M Sell
450,000
-120,000
-21% -$8.71M 3.07% 14
2025
Q4 		$43M Buy
570,000
+70,000
+14% +$4.41M 3.34% 11
2025
Q3 		$19.9M Buy
500,000
+50,608
+11% +$1.93M 1.28% 22
2025
Q2 		$19.5M Buy
+449,392
New +$17.1M 1.38% 21

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Novo Holdings A/S's APGE Position: Q1 2026 in Review

Novo Holdings A/S reduced its Apogee Therapeutics (APGE) stake by 21% in Q1 2026, selling an estimated $8.71M and leaving 450,000 shares worth $37.9M. The position accounts for 3.07% of the portfolio, ranked #14.

Novo Holdings A/S first reported a position in APGE in Q2 2025 and has held it in 4 quarters since. The position peaked at $43M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Novo Holdings A/S held 450,000 shares of Apogee Therapeutics worth $37.9M as of Q1 2026.
  • Novo Holdings A/S sold 120,000 Apogee Therapeutics shares in Q1 2026, an estimated $8.71M.
  • Apogee Therapeutics made up 3.07% of Novo Holdings A/S's portfolio in Q1 2026, its #14 holding.
  • Novo Holdings A/S first reported a position in Apogee Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Novo Holdings A/S's Apogee Therapeutics position peaked at $43M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.